Latest filing published 17 Jun 2015 for Oxford Immunotec Global PLC, €19k.
Insider track record
No signal scores available.
Closed purchases
Not enough history yet: 0 closed purchases, at least 2 are needed.
Purchases by company
Clarus Lifesciences I, L.P.: trading record in brief
Filings by Clarus Lifesciences I, L.P. span 4 companies, the busiest being Oxford Immunotec Global PLC, Avanir Pharmaceuticals and Zogenix, Inc. We count 38 filings; the first trade dates from 13 July 2010 and the latest from 16 June 2015.
In open-market terms, that means 2 purchases worth €10.3M on one side and 26 sales worth €42.5M on the other. Netting one side against the other leaves €32.2M of net selling. Unlike grants, an open-market purchase is paid for by the insider, at the market price. 2015 to date brings no purchases and 15 sales.
On 17 June 2015 came the latest disclosure, an open-market sale for €19k in Oxford Immunotec Global PLC. The last purchase on record was published on 20 September 2011, which is 5,529 days ago. Typically, a trade is published a median of 1 day after it takes place. US insiders must file a Form 4 within two business days of a trade. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Clarus Lifesciences I, L.P.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 1,529 shares@ US$14.27Ordinary SharesSEC:0001012975-15-000491:0
- 39,701 shares@ US$14.30Ordinary SharesSEC:0001012975-15-000491:1
- 25,168 shares@ US$14.27Ordinary SharesSEC:0001012975-15-000485:0
- 6,430 shares@ US$14.25Ordinary SharesSEC:0001012975-15-000485:1
- 2,662 shares@ US$14.25Ordinary SharesSEC:0001012975-15-000479:0
- 13,000 shares@ US$14.26Ordinary SharesSEC:0001012975-15-000479:1
- 8,987 shares@ US$14.32Ordinary SharesSEC:0001012975-15-000479:2
- 15,010 shares@ US$14.29Ordinary SharesSEC:0001012975-15-000473:0
- 11,014 shares@ US$14.25Ordinary SharesSEC:0001012975-15-000473:1
- 10,450 shares@ US$14.32Ordinary SharesSEC:0001012975-15-000473:2
- 27,115 shares@ US$14.53Ordinary SharesSEC:0001012975-15-000242:0
- 26,300 shares@ US$14.44Ordinary SharesSEC:0001012975-15-000242:1
- 79,307 shares@ US$14.67Ordinary SharesSEC:0001012975-15-000238:0
- 25,000 shares@ US$14.68Ordinary SharesSEC:0001012975-15-000238:1
- 50,012 shares@ US$14.61Ordinary SharesSEC:0001012975-15-000238:2
- 582,456 sharesOrdinary SharesSEC:0001012975-13-000533:0
- 1,239,308 sharesOrdinary SharesSEC:0001012975-13-000533:1
- 553,859 sharesOrdinary SharesSEC:0001012975-13-000533:2
- 203,439 sharesOrdinary SharesSEC:0001012975-13-000533:3
- 7,244,201 shares0Class A Common StockSEC:0001209191-13-042890:0
- 7,444,168 shares0Class A Common StockSEC:0001209191-12-041325:0
- 804,232 shares@ US$11.16Class A Common StockSEC:0001209191-12-041325:1
- 3,500,000 shares@ US$2.00Common StockSEC:0001012975-11-000265:0Canonical exit: 15 Dec 2011 (T+90)
- 6,669,204 shares0Common StockSEC:0001012975-10-000415:0
- 2,100,000 sharesCommon StockSEC:0001181431-10-058220:0
25 of 38 declarations
